A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment
This real-world study demonstrated that more patients who switched from TNFi to UPA had improvements in pain and affected joints compared to those who switched to a second TNFi or IL-17i.
Authors
- Sophie Barlow (ORCID: https://orcid.org/0000-0001-5604-1360)
- J. Stigler
- Xiaolan Ye (ORCID: https://orcid.org/0000-0001-7620-9642)
- Christopher D. Saffore (ORCID: https://orcid.org/0000-0003-0396-2646)
- Xenofon Baraliakos (ORCID: https://orcid.org/0000-0002-9475-9362)
- Isabel Truman (ORCID: https://orcid.org/0000-0002-6055-2902)
- Mark Edwards (ORCID: https://orcid.org/0000-0003-2584-0834)
- Atul A. Deodhar (ORCID: https://orcid.org/0000-0002-2130-1246)
- Jamie Urbanik
Institutions
- Oregon Health & Science University (US)
- AbbVie (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- Rheumazentrum Ruhrgebiet (DE)
- Ruhr University Bochum (DE)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1007/s40744-025-00786-2
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AbbVie